November 30, 2016 - By Ellis Scott · 0 Comments
Parexel International Corp (NASDAQ:PRXL) institutional sentiment decreased to 1 in 2016 Q2. Its down -0.16, from 1.16 in 2016Q1. The ratio dived, as 147 hedge funds started new or increased stock positions, while 127 trimmed and sold stakes in Parexel International Corp. The hedge funds in our partner’s database now own: 46.71 million shares, down from 47.81 million shares in 2016Q1. Also, the number of hedge funds holding Parexel International Corp in their top 10 stock positions decreased from 4 to 3 for a decrease of 1. Sold All: 31 Reduced: 96 Increased: 102 New Position: 45.
PAREXEL International Corporation is a biopharmaceutical outsourcing services company. The company has a market cap of $3.17 billion. The Firm provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology services and products to pharmaceutical, biotechnology and medical device industries. It has a 18.84 P/E ratio. The Company’s divisions include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI).
The stock closed at $58.95 during the last session. It is down 8.69% since April 27, 2016 and is downtrending. It has underperformed by 13.92% the S&P500.
Analysts await PAREXEL International Corporation (NASDAQ:PRXL) to report earnings on January, 25. They expect $0.83 earnings per share, down 7.78% or $0.07 from last year’s $0.9 per share. PRXL’s profit will be $44.63 million for 17.76 P/E if the $0.83 EPS becomes a reality. After $0.76 actual earnings per share reported by PAREXEL International Corporation for the previous quarter, Wall Street now forecasts 9.21% EPS growth.
According to Zacks Investment Research, “Parexel International Corporation is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales.”
Cryder Capital Partners Llp holds 7.51% of its portfolio in PAREXEL International Corporation for 148,906 shares. Aristotle Capital Boston Llc owns 156,770 shares or 2.21% of their US portfolio. Moreover, Lloyds Banking Group Plc has 2.11% invested in the company for 4,092 shares. The Illinois-based Jhl Capital Group Llc has invested 2.06% in the stock. Eagle Boston Investment Management Inc, a Massachusetts-based fund reported 219,828 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 insider buys, and 3 selling transactions for $526,845 net activity.
Ratings analysis reveals 17% of Parexel International’s analysts are positive. Out of 12 Wall Street analysts rating Parexel International, 2 give it “Buy”, 1 “Sell” rating, while 9 recommend “Hold”. The lowest target is $49 while the high is $78. The stock’s average target of $65.71 is 11.47% above today’s ($58.95) share price. PRXL was included in 22 notes of analysts from August 7, 2015. The stock has “Equal-Weight” rating given by First Analysis on Thursday, November 17. The stock has “Hold” rating given by Deutsche Bank on Friday, August 7. SunTrust downgraded the stock to “Hold” rating in Friday, November 11 report. The stock of PAREXEL International Corporation (NASDAQ:PRXL) has “Outperform” rating given on Friday, August 7 by Credit Suisse. Avondale maintained PAREXEL International Corporation (NASDAQ:PRXL) on Monday, April 11 with “Underperform” rating. The firm earned “Market Perform” rating on Monday, July 18 by William Blair. The rating was downgraded by Suntrust Robinson on Friday, November 11 to “Hold”. The stock of PAREXEL International Corporation (NASDAQ:PRXL) earned “Market Perform” rating by Avondale on Wednesday, October 21. Credit Suisse reinitiated the shares of PRXL in a report on Friday, August 14 with “Outperform” rating. The rating was maintained by Deutsche Bank with “Hold” on Friday, October 28.
PAREXEL International Corporation (PAREXEL), incorporated on January 3, 1983, is a biopharmaceutical outsourcing services company. The Firm provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology services and products to pharmaceutical, biotechnology and medical device industries. The Company’s divisions include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI).
More recent PAREXEL International Corporation (NASDAQ:PRXL) news were published by: Businesswire.com which released: “PAREXEL International Announces $200 Million Accelerated Share Repurchase Program” on November 22, 2016. Also Prnewswire.com published the news titled: “Wolf Popper LLP Announces Investigation of Fraud Claims on Behalf of Investors …” on November 11, 2016. Bizjournals.com‘s news article titled: “Parexel loses $160M in value after disclosing possible embezzlement” with publication date: September 01, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott